General and administrative expenses were $6.2 million and$15.3 million for the three and six months ended June 30, 2025, respectively, compared to $10.7 million and$23.1 million for the three and six months ended June 30, 2024, respectively. With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("'2510") anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by Immune ...